In the News

1832 News Items found
MSK’s Michel Sadelain Co-Authors Inaugural NEJM Frontiers in Medicine Landscape Review of CAR T Therapy
Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal of Medicine (NEJM). In the comprehensive review article, Drs. Sadelain and June highlight the emerging immunotherapy treatment for hematologic cancers known as CAR T cells, which was developed at MSK. The paper is the first in a series being published by NEJM. Known as Frontiers in Medicine, it will showcase ways that new technologies are influencing contemporary medicine and science.
Pivotal Results from Phase 3 Trial Shows Longer Overall Survival with Cabozantinib than with Placebo in Patients with Advanced Liver Cancer
New researched published in the New England Journal of Medicine and conducted by Memorial Sloan Kettering researchers offer proof of better treatment options for patients with advanced hepatocellular carcinoma the most common form of liver cancer.
In the Clinic
Pink, blue, green, and white blob on black background
Study Shows Liquid Biopsy Is Accurate for Guiding Prostate Cancer Treatment Choice
Detecting a protein in a blood sample could help doctors make treatment decisions for prostate cancer patients.
AR-V7 Validated as a Predictive Biomarker to Guide Treatment Selection for Men with Metastatic Castration-Resistant Prostate Cancer
An international team of researchers led by Howard Scher, MD, Co-Chair of the Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center (MSK), has validated a biomarker that can predict whether people with metastatic castration-resistant prostate cancer (mCRPC) may live longer if they are treated with a taxane-based chemotherapy instead of a second targeted androgen receptor–signaling inhibitor (ARSi).
In the Lab
MSK computational biologist Dana Pe'er
One by One: Single-Cell Analysis Helps Map the Cancer Landscape
Sloan Kettering Institute investigators are taking important steps toward being able to identify all the cell types in tumors. With this information, they can figure out how the cells work together.
Finding
Leukemia cells
Findings from Two Patients Shed New Light on Drug Resistance in AML
A team at MSK has discovered a previously unknown type of resistance to a new leukemia drug.
Finding
A doctor examines a mole.
Don't Scratch That Mole? Scientists Are Learning More about Inflammation and Cancer
It's not only what's inside your cells that determines your cancer risk. It's what surrounds them too.
Feature
Five scientists in a lab
Out of the Closet, into the Lab: Five LGBTQ Scientists Share Their Stories
What's it like being LGBTQ in the world of science? We asked some MSK scientists to find out.
Q&A
the Bridges team at dinner
Ten Years of Inspiration and Hope: Bridges Celebrates Its Anniversary
Learn more about Memorial Sloan Kettering’s newsletter for cancer survivors, which is celebrating its tenth year of publication.
Feature
Omar Abdel-Wahab
What Is Epigenetics, and Why Is Everyone Talking about It?
The word “epigenetic” literally means “above the genes.” Calico cats demonstrate a type of epigenetic inheritance called X-inactivation.